| abstract |
According to the present disclosure, macrocyclic compounds have been discovered that have the ability to bind PD-L1 and inhibit the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit immunomodulatory efficacy in vitro, thus making them candidate therapeutic agents for the treatment of a wide variety of diseases, including cancer and infectious diseases. |